Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Adherence to adjuvant hormonal therapy in localised breast cancer

Adherence to adjuvant hormonal therapy in localised breast cancer INTRODUCTIONAbout three‐fourths of breast cancers express the oestrogen receptor (ER) and are dependent on the molecular function of ER as a transcription factor for their survival and proliferation. The backbone of adjuvant therapy for localised ER‐positive breast cancers consists of hormonal therapies with an oral hormonal agent (either an aromatase inhibitor or tamoxifen). These therapies when taken for 5 years post‐operatively result in significant survival benefits for ER‐positive cancer patients by reducing the risk of disease recurrence and prolong survival (ATAC Trialists' Group, 2005; Breast International Group (BIG) 1‐98 Collaborative Group et al., 2005; Swain, 2005). For post‐menopausal patients, oral hormonal treatments are currently used as mono‐therapies, while, for pre‐menopausal women, they may be combined with ovarian suppression therapy (Francis et al., 2015, 2018). Prolonged hormonal therapy of 10‐year duration is recommended for high‐risk patients (Goss et al., 2016). However, hormonal therapies are associated with a wide range of adverse effects that interfere with long‐term adherence to treatment and may even compromise benefit, if therapies are discontinued prematurely. The most common adverse effects of hormonal therapies are their menopause‐type symptoms that include hot flushes, night sweats and musculoskeletal stiffness or pains (Winer et al., 2005). A general feeling of unwellness is quite bothersome for some women http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Cancer Care Wiley

Adherence to adjuvant hormonal therapy in localised breast cancer

Download PDF
8 pages

Loading next page...
 
/lp/wiley/adherence-to-adjuvant-hormonal-therapy-in-localised-breast-cancer-0sUdcuBId7
Publisher
Wiley
Copyright
© 2022 John Wiley & Sons Ltd
ISSN
0961-5423
eISSN
1365-2354
DOI
10.1111/ecc.13729
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONAbout three‐fourths of breast cancers express the oestrogen receptor (ER) and are dependent on the molecular function of ER as a transcription factor for their survival and proliferation. The backbone of adjuvant therapy for localised ER‐positive breast cancers consists of hormonal therapies with an oral hormonal agent (either an aromatase inhibitor or tamoxifen). These therapies when taken for 5 years post‐operatively result in significant survival benefits for ER‐positive cancer patients by reducing the risk of disease recurrence and prolong survival (ATAC Trialists' Group, 2005; Breast International Group (BIG) 1‐98 Collaborative Group et al., 2005; Swain, 2005). For post‐menopausal patients, oral hormonal treatments are currently used as mono‐therapies, while, for pre‐menopausal women, they may be combined with ovarian suppression therapy (Francis et al., 2015, 2018). Prolonged hormonal therapy of 10‐year duration is recommended for high‐risk patients (Goss et al., 2016). However, hormonal therapies are associated with a wide range of adverse effects that interfere with long‐term adherence to treatment and may even compromise benefit, if therapies are discontinued prematurely. The most common adverse effects of hormonal therapies are their menopause‐type symptoms that include hot flushes, night sweats and musculoskeletal stiffness or pains (Winer et al., 2005). A general feeling of unwellness is quite bothersome for some women

Journal

European Journal of Cancer Care – Wiley

Published: Nov 1, 2022

Keywords: adherence; aromatase inhibitors; compliance; predictive factors; tamoxifen

References

  • Adherence to adjuvant endocrine therapy among breast cancer survivors: A systematic review and meta‐synthesis of the qualitative literature using grounded theory
    AlOmeir, O.; Patel, N.; Donyai, P.
  • Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer
  • A nested case‐control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I‐III breast cancer
    Barron, T. I.; Cahir, C.; Sharp, L.; Bennett, K.
  • A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
    Thürlimann, B.; Keshaviah, A.; Coates, A. S.; Mouridsen, H.; Mauriac, L.; Forbes, J. F.; Paridaens, R.; Castiglione‐Gertsch, M.; Gelber, R. D.; Rabaglio, M.; Smith, I.; Wardley, A.; Price, K. N.; Goldhirsch, A.
  • Can demographic, clinical and treatment‐related factors available at hormonal therapy initiation predict non‐persistence in women with stage I‐III breast cancer?
    Cahir, C.; Barron, T. I.; Sharp, L.; Bennett, K.
  • Factors influencing adherence to adjuvant endocrine therapy in breast cancer‐treated women: Using real‐world data to inform a switch from acute to chronic disease management
    Cavazza, M.; Banks, H.; Ercolanoni, M.; Cukaj, G.; Bianchi, G.; Capri, G.; Longo, F.
  • Cutaneous leukocytoclastic vasculitis associated with letrozole
    Digklia, A.; Tzika, E.; Voutsadakis, I. A.
  • Acute cerebrovascular accident after cisplatin treatment in a patient taking letrozole
    Digklia, A.; Voutsadakis, I. A.
  • Tamoxifen for early breast cancer: An overview of the randomised trials
  • Tailoring adjuvant endocrine therapy for premenopausal breast cancer
    Francis, P. A.; Pagani, O.; Fleming, G. F.; Walley, B. A.; Colleoni, M.; Láng, I.; Gómez, H. L.; Tondini, C.; Ciruelos, E.; Burstein, H. J.; Bonnefoi, H. R.; Bellet, M.; Martino, S.; Geyer, C. E.; Goetz, M. P.; Stearns, V.; Pinotti, G.; Puglisi, F.; Spazzapan, S.
  • Adjuvant ovarian suppression in premenopausal breast cancer
    Francis, P. A.; Regan, M. M.; Fleming, G. F.; Láng, I.; Ciruelos, E.; Bellet, M.; Bonnefoi, H. R.; Climent, M. A.; Da Prada, G. A.; Burstein, H. J.; Martino, S.; Davidson, N. E.; Geyer, C. E.; Walley, B. A.; Coleman, R.; Kerbrat, P.; Buchholz, S.; Ingle, J. N.; Winer, E. P.
  • Evidence‐based approaches for the management of side‐effects of adjuvant endocrine therapy in patients with breast cancer
    Franzoi, M. A.; Agostinetto, E.; Perachino, M.; Del Mastro, L.; Azambuja, E.; Vaz‐Luis, I.; Partridge, A. H.; Lambertini, M.
  • Exercise for women receiving adjuvant therapy for breast cancer
    Furmaniak, A. C.; Menig, M.; Markes, M. H.
  • Extending aromatase‐inhibitor adjuvant therapy to 10 years
    Goss, P. E.; Ingle, J. N.; Pritchard, K. I.; Robert, N. J.; Muss, H.; Gralow, J.; Gelmon, K.; Whelan, T.; Strasser‐Weippl, K.; Rubin, S.; Sturtz, K.; Wolff, A. C.; Winer, E.; Hudis, C.; Stopeck, A.; Beck, J. T.; Kaur, J. S.; Whelan, K.; Tu, D.; Parulekar, W. R.
  • Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early‐stage breast cancer patients
    Hershman, D. L.; Kushi, L. H.; Shao, T.; Buono, D.; Kershenbaum, A.; Tsai, W. Y.; Fehrenbacher, L.; Gomez, S. L.; Miles, S.; Neugut, A. I.
  • Early discontinuation and non‐adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer
    Hershman, D. L.; Shao, T.; Kushi, L. H.; Buono, D.; Tsai, W. Y.; Fehrenbacher, L.; Kwan, M.; Gomez, S. L.; Neugut, A. I.
  • Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2‐, node‐positive, high‐risk, early breast cancer (monarchE)
    Johnston, S. R. D.; Harbeck, N.; Hegg, R.; Toi, M.; Martin, M.; Shao, Z. M.; Zhang, Q. Y.; Martinez Rodriguez, J. L.; Campone, M.; Hamilton, E.; Sohn, J.; Guarneri, V.; Okada, M.; Boyle, F.; Neven, P.; Cortés, J.; Huober, J.; Wardley, A.; Tolaney, S. M.
  • Aromatase inhibitors and the risk of cardiovascular outcomes in women with breast cancer: A population‐based cohort study
    Khosrow‐Khavar, F.; Filion, K. B.; Bouganim, N.; Suissa, S.; Azoulay, L.
  • Treatment interruption and discontinuation of hormonal therapy in hormone receptor‐positive breast cancer patients
    Mao, D.; Hachem, H.; Chang, H.; Dima, D.; Dower, J.; Wismer, M.; Erban, J. K.; Freund, K. M.; Parsons, S. K.
  • Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: A systematic review
    Murphy, C. C.; Bartholomew, L. K.; Carpentier, M. Y.; Bluethmann, S. M.; Vernon, S. W.
  • Five or more years of adjuvant endocrine therapy in breast cancer: A meta‐analysis of published randomised trials
    Petrelli, F.; Coinu, A.; Cabiddu, M.; Ghilardi, M.; Lonati, V.; Barni, S.
  • Adherence to adjuvant aromatase inhibitor therapy among postmenopausal Hispanic/Latino women with breast cancer
    Philipovskiy, A.; Campbell, A.; Heydarian, R.; Castillo, B.; Dwivedi, A. K.; McCallum, R.; Aguilera, R.; Gaur, S.; Nahleh, Z.
  • Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer
    Roberts, K. E.; Rickett, K.; Feng, S.; Vagenas, D.; Woodward, N. E.
  • Adherence and persistence to adjuvant hormonal therapy in early‐stage breast cancer patients: A population‐based retrospective cohort study in Israel
    Sella, T.; Chodick, G.
  • Adherence to adjuvant endocrine therapy in estrogen receptor‐positive breast cancer patients with regular follow‐up
    Simon, R.; Latreille, J.; Matte, C.; Desjardins, P.; Bergeron, E.
  • Fractures due to aromatase inhibitor therapy for breast cancer: A real‐world analysis of FAERS data in the past 15 years
    Song, Y.; Xu, Y. L.; Lin, Y.; Zhao, B.; Sun, Q.
  • Aromatase inhibitors‐‐A triumph of translational oncology
    Swain, S. M.
  • Cognitive impairment, aromatase inhibitors, and age
    Tralongo, P.; Di Mari, A.; Ferrau', F.
  • American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor‐positive breast cancer: Status report 2004
    Winer, E. P.; Hudis, C.; Burnstein, H. J.